Journal of Cosmetic Dermatology最新文献

Background: Eyebrows significantly influence facial aesthetics and are often linked to attractiveness and personality. Eyebrow loss and alopecia impact physical and psychological well-being. Several treatments, including mesotherapy (MT), aim to enhance eyebrow density and quality. Despite the availability of MT for hair growth, its application in eyebrow revitalization is less explored.

Aims: This study evaluates clients' perceptions and satisfaction with eyebrow MT (EB MT) using AQ skin solutions' growth factor-based MT cocktail serum.

Patients/methods: Thirty-two healthy women (ages 21-55) with thin or weakened eyebrows underwent three EB MT sessions spaced 2-4 weeks apart. Exclusion criteria included chronic diseases, allergies, and conditions like pregnancy. Each session lasted about 40 min, and "point by point" and "nappage" techniques were employed. Satisfaction and pain levels were assessed through a Numeric Rating Scale for Satisfaction (NRSS) and Pain scale, while photographic analysis and the Global Aesthetic Improvement Scale (GAIS) evaluated effectiveness.

Results: The average GAIS score was 8.28, while the NRSS satisfaction score was 8.06. Pain levels were moderately low, averaging 4.0. A high majority (90.6%) were satisfied and willing to continue treatment, with 100% recommending EB MT to others. Notable improvements in overall appearance were reported by participants.

Conclusions: EB MT demonstrated high satisfaction and low pain levels, with significant improvements in eyebrow density and appearance. This treatment is a practical option for eyebrow enhancement with a strong safety profile, motivating further clinical application.

Background: Periocular static wrinkles, which are common cosmetic concerns, lack an established effective treatment. Microneedling radio frequency (MNRF) has shown promise in skin rejuvenation; however, there is limited objective information on its long-term effectiveness with regard to periocular static wrinkles.

Aims: This study aimed to evaluate the clinical efficacy and safety of MNRF treatment for periocular static wrinkles.

Method: Eighteen participants with moderate to severe wrinkles were enrolled in this study. MNRF treatment was applied to the periocular skin using MicroRF9 microneedles, which have a depth of 0.5-1.5 mm and a pulse width of 200-300 ms. MNRF treatment was administered twice with a 1-month interval, and the participants were followed up for 6 months. The evaluation included four areas, namely the outer canthi, lower eyelid, inner canthi, and upper eyelid, by using clinical assessments and Antera 3D measurements by digitalized images and grading by clinicians.

Results: The results showed significant improvement in all four areas assessed. Participants expressed high satisfaction with the treatment, and any adverse events, such as mild pain and redness, were temporary and resolved within a week.

Conclusion: These findings confirm that MNRF is a safe and effective method for reducing periocular static wrinkles.

Background: VYC-25L is a robust, structural hyaluronic acid (HA) filler designed for facial volumizing, lifting, and contouring. It was first approved in 2019.

Methods: A group of doctors with various specialties, who have used VYC-25L extensively since it first became available in their countries (3-5 years), share clinical experience and guidance on optimal use.

Results: VYC-25L has a unique rheological and physicochemical profile that provides elevated lift capacity and enhanced projection, significant moldability immediately after injection, high levels of tissue integration, reversibility with hyaluronidase, and a long duration of clinical effects-typically lasting at least 24 months. The properties of VYC-25L have created new possibilities for nonsurgical facial medical aesthetics. However, as with any novel product, it is important that injectors recognize how best to use it for the benefit of patients. When first utilizing VYC-25L, it is advisable to start with the chin and jawline to gain familiarity with the gel characteristics before moving into other facial areas, and to consider splitting treatment over two or more sessions. Attention must also be given to injection volume, with less product typically required with VYC-25L compared to other fillers with similar indications. Key principles of good practice should be followed, including appropriate patient selection and pretreatment education, suitable choice of injection device and plane, aseptic technique, slow and careful administration method, and sufficient posttreatment follow-up.

Conclusions: By adhering to these principles, VYC-25L can produce natural-looking and highly durable outcomes without substantial safety concerns.

Background: Actinic keratosis (AK) is a common skin condition treated by dermatologists; however, the effectiveness, superiority, and potential side effects of current treatment protocols are still debated.

Aim: This study aimed to compare the effectiveness and safety of 5% fluorouracil topical cream and 1% niacinamide topical gel in patients with AK.

Methods: In a randomized clinical trial, 26 patients with 95 AK lesions were assigned to receive either 5% fluorouracil topical cream twice daily for 4 weeks or 1% niacinamide topical gel twice daily for 3 months. Photography and dermoscopy before and after treatment were used to evaluate the outcomes.

Results: The study included 26 patients who underwent randomization and treatment. Analysis of the improvement response after treatment through photography and dermoscopy scores, as well as patients' perspectives, showed that the fluorouracil group had significantly better outcomes than the niacinamide group. However, treatment complications including burning, itching, and erythema were significantly more frequent in the fluorouracil group than in the niacinamide group.

Conclusions: Although 5% fluorouracil cream is more effective than 1% niacinamide gel in treating AK lesions, it is also associated with more frequent side effects.

Background: The integration of artificial intelligence (AI) and ultrasound (US) technology is reshaping facial aesthetics, providing enhanced diagnostic precision, procedural safety, and personalized patient care. The variability in US imaging, stemming from patient anatomy, operator skills, and equipment diversity, poses challenges in achieving consistent and accurate outcomes. AI addresses these limitations by standardizing imaging protocols, automating image analysis, and supporting real-time decision-making.

Objective: To explore the applications of AI-enhanced US in facial aesthetics, focusing on its potential to improve diagnostic accuracy, procedural safety, and personalized treatments while identifying future prospects and challenges.

Methods: A comprehensive review of current literature and advancements was conducted, examining the integration of AI with US in facial aesthetics. Key areas of focus included AI algorithms for image enhancement, real-time guidance during procedures, postprocedure assessment, personalized treatment planning, and workflow optimization.

Results: AI-enhanced US significantly improved diagnostic accuracy by automating the identification of critical anatomical structures and reducing operator variability. Real-time guidance during procedures enhanced safety, reducing complications such as vascular occlusion and nerve damage. Postprocedure assessments facilitated early detection of complications and improved patient outcomes. Personalized treatment plans tailored to individual anatomy and clinical needs resulted in higher patient satisfaction. Additionally, AI optimized workflow efficiency through seamless integration with electronic health records and advanced training simulators.

Conclusion: The integration of AI and US technology represents a transformative advancement in facial aesthetics. By enhancing precision, safety, and personalization, AI-powered US sets new benchmarks in diagnostic accuracy and treatment outcomes. Despite challenges related to data diversity, ethical considerations, and training, this synergy holds immense potential to revolutionize the field, offering improved outcomes and satisfaction for practitioners and patients alike. Further research and innovation are essential to fully realize the benefits of this technology.

Background: Recent preclinical studies have demonstrated the potential efficacy of stem cell exosomes in the treatment of hair loss. However, there is a paucity of clinical studies investigating the application of exosomes for this purpose. This case series presents three patients treated with exosomes for acquired trichorrhexis nodosa (ATN), a condition characterized by hair shaft abnormalities and breakage.

Objectives: This study aims to evaluate the effectiveness and safety of utilizing mesenchymal stem cell (MSC) exosomes as a novel therapeutic approach for the management of ATN.

Methods: A standardized process was employed to prepare 0.1 mL of exosomes, which were subsequently injected into bilateral regions of the patients' scalps at 0.5-1 cm intervals on a monthly basis. Each injection comprised a total volume of 5 mL, and all three patients underwent a minimum of four treatment sessions. The comparative efficacy of the treatment was evaluated using clinical photographs, dermatoscopy, and scanning electron microscopy (SEM) for all three patients post-intervention.

Results: The hair condition of the three patients demonstrated significant improvement, characterized by increased length and density, enhanced pigmentation with a reduced presence of dusty white dots, and the disappearance of dermoscopic black dots and broken hairs. SEM analysis revealed a remarkable recovery in the hair cuticle layers. At the 1-year follow-up, hair growth essentially remained normal.

Conclusion: Exosomes derived from mesenchymal stem cells demonstrate efficacy in treating ATN, presenting a novel therapeutic approach for this condition.

Background: Refractory melasma remains a challenge in dermatology, necessitating the exploration of innovative treatments.

Aims: This study aims to evaluate the efficacy and safety of combining radiofrequency microneedling (RFM) with Cysteamine cream, applied both in-office and as a part of a home-care regimen, to treat refractory melasma.

Patients/methods: A vehicle-controlled, split-face trial was conducted on 30 Fitzpatrick skin types III and IV participants. Subjects received RFM and Cysteamine serum on one side of the face and RFM with saline on the contralateral side. Additionally, a random half-added Cysteamine cream was applied at home. The modified Melasma Area and Severity Index and VISIA skin analysis were used for assessment.

Results: Significant improvement in melasma severity and skin texture was noted on the sides treated with RFM and Cysteamine, including observable benefits from both in-office and home-based Cysteamine use with minimal adverse effects.

Conclusions: The combined approach of RFM with Cysteamine provides a promising and safe modality for managing refractory melasma, showing notable improvements.

Background: Skin barrier health is crucial for preventive and corrective skincare across all skin types. Witch hazel (Hamamelis virginiana) extracts show potential in addressing skin issues, but their efficacy in treating chronic inflammation, improving skin barrier function, and combating UV-induced oxidation requires further investigation.

Aims: To evaluate the efficacy of a novel formula containing witch hazel extracts in treating chronic inflammation, improving skin barrier function, and combating UV-induced oxidation.

Methods: We employed a novel ex vivo chronic inflammation model to assess anti-inflammatory effects, measuring key pro-inflammatory cytokines. Barrier function markers, such as loricrin and transglutaminase-1, were analyzed. An ex vivo model with UV-induced Reactive Oxygen Species (ROS) elevation was used to evaluate antioxidant properties, measuring specific ROS markers like 4-Hydroxynonenal and carbonylated protein.

Results: The novel witch hazel formula significantly reduced pro-inflammatory cytokines in both 2D and ex vivo models, including IL-6 and IL-8, demonstrating potent anti-inflammatory effects. Barrier function markers showed notable improvements compared to the inflamed condition. In the UV-induced ROS model, the formula remarkably decreased ROS levels, specifically 4-Hydroxynonenal and carbonylated protein, indicating strong antioxidant properties.

Conclusions: Our findings demonstrate that the novel witch hazel formula exhibits potent anti-inflammatory and antioxidant properties while enhancing skin barrier function. This natural, well-tolerated ingredient offers a promising treatment option for improving overall skin health, presenting new opportunities in skincare formulation and treatment strategies.